Judge Rules Mylan Did Not Infringe Novo Nordisk Patent In Wegovy Generic Case

The Novo Nordisk A/S (NYSE:NVO) attempt to block Mylan Pharmaceuticals from launching a generic version of its weight-loss drug Wegovy hit a major obstacle as the court ruled in Mylan's favor on key infringement claims related to U.S. Patent No. 9,764,003.

Read more about the NVO stock price here.

A federal district court in Delaware favored Mylan, now part of Viatris Inc. (NASDAQ:VTRS).

Novo filed the lawsuit under the Hatch-Waxman Act, alleging Mylan's Abbreviated New Drug Application (ANDA) for a generic semaglutide product infringes five patents tied to its popular weight loss drug Wegovy (semaglutide).

Also Read: Does Higher Dose Of Wegovy Result In More Weight Loss? Novo Nordisk Seeks European Approval

The suit claims Mylan's generic would violate patent protections listed in the FDA's Orange Book, thus constituting an act of infringement.

However, Mylan contended that as a drug manufacturer, not a prescriber, it ...